Skip to main content

Table 4 Univariable and multivariable linear regression analyses of factors associated with overall satisfaction with medication (n = 78)

From: Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

  Univariable analysis Multivariable analysis
B (95% CI) p-value B (95% CI) p-value
Age 0.019 (− 0.04;0.08) 0.55
Gender −0.97 (−2.6;0.6) 0.25
Expectations effectiveness 0.54 (−0.15;1.2) 0.12
Expectations side-effects −0.10 (− 0.85;0.65) 0.79
FVC % predicted 0.004 (−0.02;0.03) 0.76
DLCO % predicted 0.008 (−0.02;0.04) 0.60   
Change in FVC % predicted* 0.05 (−0.005;0.01) 0.079 0.026 (−0.05;0.10) 0.64
Change in DLCO % predicted* −0.04 (− 0.08;0.01) 0.11
Antifibrotic drug 0.24 (−0.62;1.1) 0.58
VAS - cough −0.23 (− 0.39;-0.07) 0.005   
VAS – dyspnea −0.41 (− 0.56;-0.26) < 0.001   
VAS - general complaints 0.36 (0.15;0.57) 0.001 0.04 (−0.34;0.42) 0.84
HADS – anxiety score −0.30 (− 0.47;-0.14) 0.001 − 0.23 (− 0.63;0.17) 0.24
HADS – depression score − 0.24 (− 0.35;-0.13) < 0.001 −0.01 (− 0.29;0.28) 0.95
Experiences effectiveness 1.2 (0.6;1.75) < 0.001 0.95 (0.22;1.67) 0.01
Experiences side-effects −0.53 (− 0.87;-0.18) 0.003 0.07 (− 0.67;0.82) 0.84
Experiences ease of use −0.99 (−1.8;-0.17) 0.019 −0.34 (−1.99;1.31) 0.68
Severity score side-effects −0.07 (− 0.11;− 0.03) 0.001 -0.03 (− 0.11;0.052) 0.49
  1. FVC forced vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, HADS hospital anxiety and depression scale, VAS visual analogue scale, *change in FVC and DLCO between baseline and six months